Development of immunotherapy targeting minor antigens

我们已经确定了新的次要组织相容性抗原（mHAg）表位，可以作为良好的目标免疫治疗后，异基因血液和骨髓移植复发性恶性肿瘤。利用从移植后受者外周血中分离的CTL克隆，已经确定了CTSH、HMSD、HMHA 1、BCL 2A1、SLC 1A5、UGT 2B17、P2RX 7、DPT 1编码的8种新的mHAg。我们首次证明了针对DNA池的全基因组分析和使用国际HapMap基因组数据库的关联研究都是可以快速识别感兴趣的mHAg的强大方法。

We have identified novel minor histocompatibility antigen (mHAg) epitopes that could serve as good targets for immunotherapy against recurrent malignancies following allogeneic blood and marrow transplantation. Using CTL clones isolated from recipient peripheral blood post-transplant, eight novel mHAgs encoded by CTSH, HMSD, HMHA1, BCL2A1, SLC1A5, UGT2B17, P2RX7, DPT1 have been determined. We have shown for the first time that both a whole genome analysis against the DNA pools and also an association study using the International HapMap genomic database are powerful methods that can quickly identify mHAgs of interest.